OCUL
Ocular Therapeutix, Inc.
OCUL trails on the overall score without a compensating advantage in the available component scores.
OSCR
Oscar Health, Inc.
OSCR has the edge over OCUL overall, supported by stronger fundamentals and lower modeled downside.
OCUL Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Weak | |
| Unavailable |
OCUL's revenue is currently stable, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
OCUL PE Valuation
OCUL has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
OCUL Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| -- | |
| Limited | |
| Moderate |
Analysts expect OCUL's losses to grow, with revenue growing.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
OCUL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.44 | -$0.04 |
| Q2 2026 | -$1.40 | -$0.16 |
| Q1 2026 | -$1.44 | -$0.33 |
| Q4 2025 | -$1.42 | -$0.20 |
| Q3 2025 | -$1.40 | -$0.31 |
| Q2 2025 | -$1.24 | -$0.12 |
| Q1 2025 | -$1.11 | +$0.01 |
| Q4 2024 | -$1.22 | -$0.20 |
OCUL is still losing money, but less than at its worst: $1.44 per share over the past year, against $2.56 at its worst in late 2020.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over OCUL on earnings quality, reporting a profit while its opponent remains loss making.
OCUL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $12.9M | -11% |
| Q2 2026 | $13.5M | +0.1% |
| Q1 2026 | $10.8M | +0.8% |
| Q4 2025 | $13.3M | -22% |
| Q3 2025 | $14.5M | -5.7% |
| Q2 2025 | $13.5M | -18% |
| Q1 2025 | $10.7M | -28% |
| Q4 2024 | $17.1M | +15% |
OCUL's revenue has slid since its 2024 peak: $13M last quarter, down 11% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -760% | -288 points |
| Q2 2026 | -609% | -107 points |
| Q1 2026 | -865% | -268 points |
| Q4 2025 | -526% | -230 points |
| Q3 2025 | -472% | -174 points |
| Q2 2025 | -503% | -237 points |
| Q1 2025 | -597% | -384 points |
| Q4 2024 | -296% | -161 points |
OCUL's operating margin was −760% last quarter, down 288 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over OCUL on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over OCUL on profitability, with a higher operating margin.
OCUL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$68.7M | -$11.9M |
| Q2 2026 | -$70.6M | -$14.2M |
| Q1 2026 | -$70.7M | -$24.1M |
| Q4 2025 | -$57.1M | -$17.5M |
| Q3 2025 | -$56.7M | -$20.1M |
| Q2 2025 | -$56.5M | -$30.9M |
| Q1 2025 | -$46.6M | -$12.5M |
| Q4 2024 | -$39.6M | -$16.7M |
OCUL has burned cash in almost every quarter: −$267M over the past year, against −$199M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over OCUL on cash generation, producing positive trailing cash flow while its opponent burns cash.
OCUL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +563K shares |
| 1 year | +23% | +41.6M shares |
| 3 years | +189% | +147M shares |
| 5 years | +175% | +143M shares |
| Available history | +398% | +180M shares |
OCUL has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
OCUL Net Leverage
OCUL's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
OCUL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.5 | Neutral |
| Stochastic | 10.7 | Oversold |
OCUL's weekly RSI is 36 (neutral) and its Stochastic is 11 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
OCUL PE vs Healthcare Sector
OCUL has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
OCUL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $7.17 | 12% below |
| 20 week MA | $8.73 | 28% below |
| 50 week MA | $9.37 | 33% below |
| 100 week MA | $9.49 | 34% below |
| 200 week MA | $7.82 | 20% below |
OCUL is in a downtrend: it's below all five of its weekly moving averages, and 20% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over OCUL on trend strength, trading above more of its moving averages.
OCUL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $4.19 | $22.1 | +427% |
| 2021 | $22.1 | $7.22 | -67% |
| 2022 | $7.22 | $2.67 | -63% |
| 2023 | $2.67 | $4.46 | +67% |
| 2024 | $4.46 | $8.44 | +89% |
| 2025 | $8.44 | $12.6 | +49% |
| 2026 YTD | $12.6 | $6.28 | -50% |
OCUL's yearly returns have swung widely, from +427% in 2020 to −67% in 2021. It's down 50% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over OCUL on returns for 2026, with the stronger performance.